VLTR-559 / Valitor - LARVOL DELTA

Valitor Presents Preclinical Data Demonstrating VLTR-559 Achieves Superior Durability and Sustained Anti-VEGF Activity with a Favorable Safety Profile as a Treatment for Wet AMD (GlobeNewswire) - "Preclinical results support 6-month dosing, demonstrating VLTR-559’s substantially longer ocular half-life, with high drug concentrations retained in the retina compared to current anti-VEGF standard of care....VLTR-559 was well tolerated at target clinical dose with a safety profile similar to approved short-acting anti-VEGF therapies for wet AMD. Data featured in an oral presentation at the at the Eyecelerator Conference held in conjunction with the AAO 2025 Annual Meeting."

Preclinical • Wet Age-related Macular Degeneration

Valitor Presents New Preclinical Data Demonstrating VLTR-559, an Anti-VEGF Drug Candidate for Wet AMD with a Twice-Yearly “Treat-and-Release” Regimen, Exhibits Favorable Safety Profile Similar to Short-Acting Anti-VEGFs (GlobeNewswire) - "Positive safety results observed across multiple measures of eye health, including intraocular pressure and ophthalmic examination scores. Data featured in a presentation at the Ophthalmology Futures Retina Forum."

Preclinical • Wet Age-related Macular Degeneration

Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology’s Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire) - "The lead development candidate, VLTR-559, is a long-acting anti-VEGF biologic designed to enable twice-yearly dosing for the treatment of wet age-related macular degeneration (AMD) for improved long-term outcomes and reduced clinical treatment costs and burden: Engineered to both extend the intravitreal half-life and increase the potency of anti-VEGF therapy; Could enable a reduced twice-yearly dosing frequency, versus eight to twelve weeks for current standard-of-care anti-VEGFs; Potent VEGF inhibition and high drug concentration found in target tissues in vivo; Preclinical safety profile consistent with marketed anti-VEGF biologics; Advancing through IND-enabling activities with a Phase 1 study expected to begin in 2026."

New P1 trial • Preclinical • Wet Age-related Macular Degeneration